TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03991598

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: Exercise program in communities / Exercise program at home
Study: NCT00241969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral and Nutrition Treatment
Description: This intervention will combine individualized nutrition counseling that targets increasing energy and fat intake and parent training of effective behavioral child management skills. The treatment is delivered through 8 weekly sessions followed by 4 monthly sessions, each lasting around 60 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education and Attention Control
Description: This intervention will provide information about a number of aspects of their child's CF care and also provides anticipatory guidance for preschoolers.The treatment is delivered through 8 weekly sessions followed by 4 monthly sessions, each lasting around 60 minutes.
Study: NCT03450148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pavlok wristband with electric stimulus
Description: it is a device for various behavior modifications in the form of wristband which participants will wear on the wrist. Device has maximum voltage of 0-500 volts, delivers a electric stimulus for a maximum of 1 sec and average duration of 0.2 secs

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pavlok wristband without electric stimulus
Description: it is a device for various behavior modifications in the form of wristband which participants will wear on the wrist. Participants will not receive any electric stimulus since this feature will be turned off.
Study: NCT01340040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-573
Description: MEDI-573 will be administrated once 7 days in Cohort 1 and 2, and once every 21 days in Cohort 3 as a IV infusion as part of a 21-day treatment cycle.
Study: NCT01674517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast sodium chewable tablets 4mg and 5mg
Description: Montelukast sodium chewable tablets 4mg and 5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast sodium chewable tablets 4mg and 5mg
Description: Montelukast sodium chewable tablets 4mg and 5mg
Study: NCT01940289

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Algometric meter readings for perception of pain

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Algometric meter readings for perception of pain
Study: NCT02941419

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet lysate
Description: Autologous intramuscular platelet lysate injection for patients with peripheral arterial disease
Study: NCT02992444

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard adhesive strip
Description: This is a standard adhesive strip (hydrocolloid)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental adhesive strip
Description: This is a strip of a newly developed adhesive.
Study: NCT05090475

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Academic detailing intervention
Description: Academic detailing or educational outreach is a method based on scientific data with the help of educated A-team members in the form of direct (face-to-face) interactions, prescribing practices change and adherence improves according to the application of currently valid therapeutic guidelines
Study: NCT03318783

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK2256294
Description: GSK2256294 will be administered in a single dose once daily enteral for a duration of 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered in a single dose once daily enteral for a duration of 10 days.
Study: NCT01558778

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: Undergo mechanical stimulation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: musculoskeletal complications management/prevention
Description: Undergo mechanical stimulation
Study: NCT02605096

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Magnetic Resonance Imaging Scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: X-ray
Description: X-ray exam (conventional radiography)
Study: NCT04609839

Intervention type: OTHER
Intervention: Follow-up of patients with COVID-19
Description: The presence of sequelae, number of re-hospitalizations, date of death and cost of health expenditure will be collected.~The Quality of life score (SF-36 questionnaire) and the Pittsburgh sleep quality index (PSQI questionnaire) will be completed by patients.
Study: NCT04647318

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion focused imagery, relaxation imagery and control task
Description: Participants will engage in three tasks (control task, relaxation imagery, and CFI) every three days on a total of 3-4 occasions. Audio-recordings of scripts will be used for both relaxation and compassion imagery. The 4-minute relaxation imagery will involve the following components (i) breathing deeply and bringing mindful awareness to the breath, (ii) relaxing the body, (iii) multisensory mental imagery of a beach or a forest, (iv) noticing feelings that arise. The 4-minute self-compassion imagery scripts will involve the following components: (i) informing participants that showing ourselves self-compassion is an effective emotional-regulation tool, (ii) breathing deeply and attending mindfully to the breath, (iii) imagining oneself embodying the four characteristics of compassion according to Gilbert5, (iv) imagine wishing oneself free of suffering using a warm voice tone and (v) noticing feelings that arise. The control task will involve reading a local city culture magazine.
Study: NCT02419963

Intervention type: PROCEDURE
Group type: OTHER
Intervention: endoscopy for tissue biopsy
Description: endoscopy to obtain tissue biopsy for analysis of biomarker status

Intervention type: PROCEDURE
Group type: OTHER
Intervention: endoscopy for tissue biopsy
Description: endoscopy to obtain tissue biopsy for analysis of biomarker status

Intervention type: OTHER
Group type: OTHER
Intervention: Blood Sample
Description: Blood draw to evaluate serotonin and Vit D level.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood Sample
Description: Blood draw to evaluate serotonin and Vit D level.

Intervention type: OTHER
Group type: OTHER
Intervention: Stool Sample
Description: Stool sample to evaluate microbiome fingerprint.

Intervention type: OTHER
Group type: OTHER
Intervention: Stool Sample
Description: Stool sample to evaluate microbiome fingerprint.
Study: NCT01717170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab (4 mg/kg or 8 mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab (4 mg/kg or 8 mg/kg)
Study: NCT02390661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Penrose drain placement
Description: A penrose drain will be placed in the lumpectomy cavity after removal of the irradiation catheter
Study: NCT05810441

Intervention type: OTHER
Intervention: Evaluation of diagnostic accuracy of anti-ttg-m
Description: Mucosal anti-ttg evaluated in intestinal biopsy samples

Intervention type: OTHER
Intervention: Evaluation of diagnostic accuracy of anti-ttg-m
Description: Mucosal anti-ttg evaluated in intestinal biopsy samples

Intervention type: OTHER
Intervention: Evaluation of diagnostic accuracy of anti-ttg-m
Description: Mucosal anti-ttg evaluated in intestinal biopsy samples
Study: NCT01732341

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STENTYS self-apposing stent
Description: Intervention to treat STEMI with the STENTYS self-apposing stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VISION balloon-expandable stent
Description: STEMI treatment with a VISION balloon-expandable stent~--------------------------------------------------------------------------------
Study: NCT04846855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: local anaesthetic injection
Description: Realization by the anesthesiologist of the local anesthesia by single dose of ropivacaine 0.35% in perinervous under ultrasound with distraction by a tablette.
Study: NCT02368899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Alcohol Misuse Intervention
Description: Interventionaire© is a computerized alcohol misuse intervention that includes a normative feedback component unique in its micro-targeting of alcohol use feedback based on participant demographic characteristics (race/ethnicity, gender, and age), drawing population normative data from the National Surveys on Drug Use and Health. This represents a novel use of epidemiological data to inform clinical services.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control (AC)
Description: These products are designed for entertainment and educational purposes only. No medical claims are made for them and, the participant's interaction with them should be conceptually unrelated to alcohol use behavior.In order to avoid any carryover effect from comparing two active treatments, we have chosen to use a simple attention control condition that is not expected to exert any real intervention effect. In that way, the effect size estimate of the intervention can be readily calculated. No research data will be collected as part of the AC, beyond the amount of time spent on the program.
Study: NCT02765386

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid fittings for cochlear implant recipients
Study: NCT01052389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Patients allocated to aripiprazole will be prescribed daily oral dose of drug, based on individual response and side-effects. Suggested starting dose will be 10 mg/day and dose range will be 10-30 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Patients allocated to olanzapine will be prescribed daily oral dose of drug, based on individual patients' response and side-effect burden. Suggested starting dose will be 5 mg/day and dose range will be 10-20 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: Patients allocated to haloperidol FGA arm will be prescribed daily oral dose of drug, based on individual patients' response and side-effect burden.~Suggested starting dose will be 1-3 mg/day and dose range 3-10 mg/day (chlorpromazine equivalents: suggested starting dose 50-100 mg/day; dose range 150-300 mg/day).
Study: NCT00505414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol in the Titration Phase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine in the Maintenance Phase
Description: Participant started the trials with 45 mg morphine controlled release twice daily. Upward titration could then occur at a minimum of 3-day intervals in increments of 15 mg morphine twice daily. The maximum dose of morphine controlled release was 90 mg twice daily. Downward titration (but not below 45 mg twice daily) was permitted. In the maintenance phase participants continued on the dose level established in titration phase.~Participants randomized to the morphine arm remained on morphine if they qualified for the maintenance phase of the study. The participants were maintained on the dose established at the end of the titration phase. The adverse events listed were documented in the maintenance phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo in the Maintenance Phase after Tapentadol in the Titration Phase
Description: Participant randomized to placebo in the maintenance phase received 100 mg tapentadol prolonged release twice daily for 3 days to taper them off of the tapentadol dose they had received in the titration period. From the fourth day of the maintenance period onwards they received placebo twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol in the Maintenance Phase
Description: The participants re-randomized to receive tapentadol prolonged release in the maintenance phase were maintained on the dose established in the titration phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine in the Titration Phase
Description: After signing informed consent eligible subjects were randomized to receive morphine controlled release. The oral medication was taken twice daily, morning and evening every 12 hours (with a minimum of 6 hours between doses). Participant started the trials with 45 mg morphine controlled release twice daily. Upward titration could then occur at a minimum of 3-day intervals in increments of 15 mg morphine twice daily. The maximum dose of morphine controlled release was 90 mg twice daily. Downward titration (but not below 45 mg twice daily) was permitted.
Study: NCT04660578

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACCSS
Description: A. Chohan Continuous Squeezing Suture (ACCSS)
Study: NCT04128124

Intervention type: OTHER
Intervention: processing signals of airway pressure and airway flow to calculate entropy
Description: processing of previously recorded data from a dedicated software of airway pressure and airway flow in order to calculate entropy

Intervention type: OTHER
Intervention: processing signals of airway pressure and airway flow to calculate entropy
Description: processing of previously recorded data from a dedicated software of airway pressure and airway flow in order to calculate entropy
Study: NCT01397240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albis Tab
Description: 2 Tab, twice a day, 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 Tab, twice a day, 12 weeks
Study: NCT03503383

Intervention type: BEHAVIORAL
Intervention: Patient Health Questionnaire-9
Description: PHQ-9 for assessing and monitoring depression severity

Intervention type: BEHAVIORAL
Intervention: Patient Health Questionnaire-9
Description: PHQ-9 for assessing and monitoring depression severity

Intervention type: BEHAVIORAL
Intervention: Generalized Anxiety Disorder Scale (GAD-7)
Description: to diagnose generalized anxiety disorder, the GAD-7 also proved to have good sensitivity and specificity as a screener for panic, social anxiety, and post-traumatic stress disorder

Intervention type: BEHAVIORAL
Intervention: Generalized Anxiety Disorder Scale (GAD-7)
Description: to diagnose generalized anxiety disorder, the GAD-7 also proved to have good sensitivity and specificity as a screener for panic, social anxiety, and post-traumatic stress disorder
Study: NCT03367910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplant
Description: 150mL of FMT product RBX2660 delivered via enema
Study: NCT01317706

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of cervical status
Description: Assessment of cervical status based on Bishop score versus sonographically measured cervical length

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of cervical status
Description: Assessment of cervical status based on Bishop score versus sonographically measured cervical length
Study: NCT01560871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity IMT plus walking
Description: The IMT intensity was set at 60% of PImax which was reassessed weekly. Frequency: 5x/week; 1x/day preferred. 6 Interval Levels: (6 efforts at each level): (1) 60s rest interval; (2) 45s rest interval; (3) 30s rest interval; (4) 15s rest interval; (5)10s rest interval; (6) 5s rest interval, trained to exhaustion.~For the walking program, it was the same as the one for the control group.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Low-intensity IMT plus walking
Description: The IMT training was 3 sets of 10 repetitions, or when the participant felt tired. Participants returned to our facility every week to reassess PImax.~For the walking program, each participant was given a pedometer and a heart rate monitor to track daily step counts and heart rate. The walking program consisted of walking every day at an intensity of somewhat hard to hard on the Borg's Rating of Perceived Exertion scale. Participants began at least 10 to 15 minutes, once to twice a day, for 7 days a week, and eventually progressed to 45-50 minutes a day by the end of the six weeks, if they could tolerate.
Study: NCT02643745

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nephrology Intervention
Description: 1. pre-operative study:~   * Kidney function: creatinine, Glomerular filtration rate (GFR) and presence albuminuria or proteinuria. Assessment whether there is a functional component added.~  * Discard presence of renal disease: renovascular disease, glomerular disease, toxic, etc.~2. optimise the patient' s overall condition with a pre-operative strategy:~   * Obesity control~  * Control protein, caloric, salt intake~  * Stop smoking~  * Good glycemic control~  * Start ACEI/ARA II if there is proteinuria~  * Start additional antihypertensive drug if required~  * Start hypolipemic treatment if required~  * Start hyperuricemia treatment if required~  * Start AAS, clopidogrel if it is necessary (prophylaxis)~  * Phosphate control~  * Anemia control~  * Metabolic acidosis correction
Study: NCT02004106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6895882
Description: Participants will receive RO6895882 at different dose levels and schedules defined in respective arms as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6895882
Description: Participants will receive RO6895882 at different dose levels and schedules defined in respective arms as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6895882
Description: Participants will receive RO6895882 at different dose levels and schedules defined in respective arms as IV infusion.
Study: NCT02933307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HealthPatch
Description: The HealthPatch (Vital Connect) is a wireless patch and continuously measures single-lead ECG, heart rate, respiratory rate, stress, skin temperature, body posture and steps

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ViSi Mobile
Description: ViSi Mobile (Sotera Wireless) is wireless device that is able to continuously measure all important vital parameters: ECG, heart rate, oxygen saturation, blood pressure, respiratory rate and skin temperature.
Study: NCT01010997

Intervention type: DEVICE
Intervention: Foresee Home
Description: using the Foresee home device

Intervention type: DEVICE
Intervention: Foresee Home
Description: using the Foresee home device
Study: NCT03307122

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Infant Formula 1
Description: Routine infant formula with probiotic

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Infant Formula 2
Description: Routine infant formula with probiotic and prebiotic
Study: NCT01721746

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-936558

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study: NCT03326752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DV281
Description: - Dose Escalation will be the preliminary dose finding phase of the study. Subjects will be enrolled to available Dosing Cohorts.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breath Actuated Nebulizer
Description: Breath-actuated, electronic system designed to aerosolize liquid medication.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breath Actuated Nebulizer
Description: Breath-actuated, electronic system designed to aerosolize liquid medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DV281 (RP2D)
Description: - Dose Expansion will be enrolled into 4 groups based on NSCLC characteristics.
Study: NCT03127878

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study: NCT04532762

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasal spray
Description: Application of a nasal spray

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: nasal spray
Description: Application of a nasal spray
Study: NCT00738985

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ezetimibe/simvastatin 10/20 mg + placebo
Description: Patients will receive placebo (sugar tablets) for up to 22 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ezetimibe/simvastatin 10/20 mg + MK0524A
Description: ezetimibe (+) simvastatin 10/20 mg for 18 weeks. Tablets
Study: NCT00630136

Intervention type: BEHAVIORAL
Intervention: interview
Description: The parent/LAR who has consented to have their child undergo an outpatient endoscopy procedure will be interviewed prior to the procedure being performed.
Study: NCT01193218

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (low dose)
Description: Placebo tablets once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (low dose)
Description: Placebo tablets once a day
Study: NCT03326752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Approved Anti-PD-1 Inhibitor
Description: FDA approved Anti-PD-1 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Approved Anti-PD-1 Inhibitor
Description: FDA approved Anti-PD-1 Inhibitor
Study: NCT04478500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: Participants will be randomly assigned to receive either Minocycline 100mg twice daily or Placebo.~Comprehensive testing will be performed at baseline, and at the end of the 12 week intervention phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Minocycline
Description: Participants will be randomly assigned to receive either Minocycline 100mg twice daily or Placebo.~Comprehensive testing will be performed at baseline, and at the end of the 12 week intervention phase.
Study: NCT03933020

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR active video game intervention
Description: The Microsoft VR active game program will consist of 3 weekly sessions of 45 minutes each combining 3 different types of exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational session
Description: This consists of two education discussion sessions on the benefits of exercise for people with MS. The investigator MS specialists will conduct these sessions either by phone or at the time of a clinic visit and will also discuss difficulties encountered by participants with adherence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Management of Physical Activity
Description: Routine discussion of lifestyle factors including physical activity during clinic visits
Study: NCT04006509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prenatally Delivered Lactation Educational Program
Description: The support person (SP) of mothers at risk for preterm birth will be educated on how to use a breast pump and instructions regarding breast milk expression and have a pump in their hospital room